Home » Stocks » ACST

Acasti Pharma Inc. (ACST)

Stock Price: $0.552 USD -0.018 (-3.07%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $0.550 -0.002 (-0.38%) Jun 11, 7:58 PM
Market Cap 113.35M
Revenue (ttm) 81,000
Net Income (ttm) 3.07M
Shares Out 208.38M
EPS (ttm) 0.03
PE Ratio 20.46
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $0.552
Previous Close $0.570
Change ($) -0.018
Change (%) -3.07%
Day's Open 0.568
Day's Range 0.542 - 0.570
Day's Volume 9,376,878
52-Week Range 0.171 - 1.220

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Penny stocks to buy under $5? Check these 3 out for your watchlist The post Best Penny Stocks to Buy Under $5?

Other stocks mentioned: CIDM, SOLO
1 week ago - PennyStocks

Best biotech penny stocks to buy during the crypto crash? Check these 3 out The post Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% appeared first on Penny Stocks to Buy, Picks, New...

Other stocks mentioned: ADXS, AGEN
3 weeks ago - PennyStocks

LAVAL, Québec, May 17, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announced that, on May 11, 2021, the Company received notice from the ...

3 weeks ago - GlobeNewsWire

NEW YORK, May 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Domtar Corporation (NYSE: UFS) concerning potential vio...

Other stocks mentioned: CHMA, FOE, UFS
4 weeks ago - PRNewsWire

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Acasti Pharma In...

1 month ago - Business Wire

Shares of Acasti Pharma, Inc. (NASDAQ:ACST) fell to the 40-cent support level. Then they rallied and hit resistance at the 58 cents level and are selling off again.

1 month ago - Benzinga

Acasti Pharma Inc (NASDAQ: ACST) has agreed to acquire privately-held Grace Therapeutics Inc in an all-stock transaction. After the consummation of the deal, Acasti would own approximately 55% of the co...

1 month ago - Benzinga

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Acasti Pharma Inc. (NASDAQ: ACST) and Grace Therapeutics Inc. is fair to Acasti sha...

1 month ago - Business Wire

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has announced a definitive agreement to acquire Grace Therapeutics Inc, a privately-held biopharmaceutical company developing drug delivery technologies for th...

1 month ago - Proactive Investors

Which penny stocks should you know about in 2021? Take a look at these 3 The post 3 Penny Stocks That Investors Need to Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information |...

Other stocks mentioned: ASRT, TTOO
1 month ago - PennyStocks

Grace provides Acasti with a pipeline of rare and orphan disease programs, including 3 clinical stage assets that have received Orphan Drug Designation from the FDA

1 month ago - GlobeNewsWire

Are penny stocks under $2 worth it? Take a look at these 3 to decide The post Best Penny Stocks to Buy Under $2?

Other stocks mentioned: LKCO, TRCH
1 month ago - PennyStocks

The future course of ACST stock depends largely on the company's lead drug candidate, CaPre. Any good news could send the shares higher.

2 months ago - InvestorPlace

From time to time, ACST stock tends to have massive price spikes. It's too volatile for a long-term position, but may be a trader's paradise.

2 months ago - InvestorPlace

LAVAL, Quebec, March 08, 2021 (GLOBE NEWSWIRE) -- As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) is providin...

3 months ago - GlobeNewsWire

TRILOGY 2 study on CaPre did not meet its primary endpoint CaPre was a krill-oil derived prescription drug designed to treat hypertriglyceridemia What Acasti Pharma does: Acasti Pharma Inc (NASDAQ:ACST)...

3 months ago - Proactive Investors

Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics...

Other stocks mentioned: CORT
4 months ago - Benzinga

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) (FRA:A1PA), which is currently going through a review process aimed at enhancing shareholder value, posted Tuesday its fiscal third-quarter results to end-Dece...

4 months ago - Proactive Investors

LAVAL, Quebec, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) today announced its operating and financial results for the third quarter of f...

4 months ago - GlobeNewsWire

Acasti Pharma (ACST) stock is on the rise Monday with heavy trading of its shares despite a lack of news concerning the company. The post ACST Stock Alert: 13 Things for Acasti Pharma Investors to Know ...

5 months ago - InvestorPlace

Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

5 months ago - Zacks Investment Research

LAVAL, Québec, Dec. 23, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company's management and B...

5 months ago - GlobeNewsWire

ACST stock is up more than 100% on Wednesday without any news about Acasti Pharma. Here's what you should know.

5 months ago - InvestorPlace

LAVAL, Quebec, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) today provided a business update and announced its operating and financial res...

6 months ago - GlobeNewsWire

LAVAL, Québec, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST – TSX-V: ACST), announces the voting results for the matters listed in its management in...

8 months ago - GlobeNewsWire

Additional analyses of TRILOGY data underway Additional analyses of TRILOGY data underway

8 months ago - GlobeNewsWire

LAVAL, Québec, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has appointed seasoned financial executive Brian D. Ford...

8 months ago - GlobeNewsWire

LAVAL, Québec, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has filed and mailed the information circular and manage...

9 months ago - GlobeNewsWire

CaPre achieved a 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint CaPre achieved a 30.4% median reduction ...

9 months ago - GlobeNewsWire

Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

9 months ago - Zacks Investment Research

LAVAL, Québec, July 31, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and co...

10 months ago - GlobeNewsWire

Acasti Pharma (NASDAQ: ACST) shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share.

11 months ago - Benzinga

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q4 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Identifies “Triglyceride Normalization” phenomenon prior to patient randomization and treatment  as likely contributor to unusually high placebo effect in TRILOGY 1

11 months ago - GlobeNewsWire

Plans to report summary of Trilogy 1 data on June 29, 2020 conference call Plans to report summary of Trilogy 1 data on June 29, 2020 conference call

11 months ago - GlobeNewsWire

FDA response expected on or before June 30, 2020

1 year ago - GlobeNewsWire

Expands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids Expands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids

1 year ago - GlobeNewsWire

LAVAL, Québec, April 01, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and   ...

1 year ago - GlobeNewsWire

LAVAL, Québec, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and com...

1 year ago - GlobeNewsWire

It doesn't look good for Acasti Pharma stock. If they plan on doubling-down on CaPre, they need more capital.

1 year ago - InvestorPlace

Acasti Pharma stock plunged after the company reported negative trial results. The company's road ahead is filled with risks.

1 year ago - InvestorPlace

Acasti Pharma stock collapsed following an unsuccessful Phase 3 clinical trial. But even this major setback isn't the only headwind impacting shares.

1 year ago - InvestorPlace

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Acasti Pharma stock jumped higher last year on the potential of Acasti’s krill-oil extract CaPre. But a closer examination of its Phase 3 results suggests not all is well with the company.

1 year ago - InvestorPlace

Acasti's Phase 3 trial of CaPre, aimed at patients with high levels of triglycerides, isn't working out, explaining why the stock is down 69.11% to start 2020. One of the primary causes of concern with ...

1 year ago - InvestorPlace

Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1

1 year ago - GlobeNewsWire

Acasti Pharma lost $118 million in market capitalization on January 13. That makes Acasti Pharma stock a liability, not a bargain.

1 year ago - InvestorPlace

Acasti Pharma stock plunged after disappointing TRILOGY 1 trial results. TRILOGY 2 results in February mark the company's last chance.

1 year ago - InvestorPlace

Following unsuccessful Phase 3 clinical trial results for its core CaPre treatment, Acasti and ACST stock look doomed. The post The Future Doesn’t Look Too Bright For Acasti Pharma Stock appeared first ...

1 year ago - InvestorPlace

Acasti hopes a second study of its CaPre drug, due for release next month, shows better results, but most investors have left ACST stock. The post Acasti’s Losing Drug and ACST Stock Are Not for Weak He...

1 year ago - InvestorPlace

About ACST

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Industry
Biotechnology
CEO
Janelle D'Alvise
Employees
32
Stock Exchange
NASDAQ
Ticker Symbol
ACST
Full Company Profile

Financial Performance

Financial numbers in millions CAD.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for Acasti Pharma stock is "Hold" and the 12-month stock price forecast is 2.52.

Price Target
$2.52
Analyst Consensus: Hold